Evidence map›Paper›PMID 42015912›Full record

ArticleChemistry (Weinheim an der Bergstrasse, Germany)2026

C-Terminal Nucleobase Modification Amplifies Peptide-Mediated Liposome Fusion.

Laura Morbiato, Giacomo Bettin, Chiara Dalla Torre, Lorenzo Stella, Marta De Zotti

Abstract read
In one paragraph

Article in Chemistry (Weinheim an der Bergstrasse, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. C-Terminal Nucleobase Modification Amplifies Peptide-Mediated Liposome Fusion.Chemistry (Weinheim an der Bergstrasse, Germany) · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Laura MorbiatoDepartment of Chemical Sciences, University of Padova, Padova, Italy.
Giacomo BettinDepartment of Chemical Sciences, University of Padova, Padova, Italy.
Chiara Dalla TorreDepartment of Chemical Sciences, University of Padova, Padova, Italy.
Lorenzo StellaDepartment of Chemical Science and Technology, University of Rome Tor Vergata, Rome, Italy.
Marta De ZottiDepartment of Chemical Sciences, University of Padova, Padova, Italy.

Funding

Dipartimento di Scienze Chimiche, Università degli Studi di Padova DEZO_BIRD23_01 - BIRD 2023 - SID 2023Italian Ministry for University and Research PRIN 2022 PNRRMinistero dell'Università e della Ricerca PRIN 2022 PNRR P2022NEJ8KUniversity of Padova Italy DEZO_BIRD23_01
6 · The paper itself

Abstract

The discovery of novel fusion peptides with enhanced properties is crucial for advancing our understanding of membrane fusion processes and developing more efficient tools for biotechnology and medicine. Currently, fusion peptides are mostly identified as portions of viral fusion proteins, and this limits their versatility. This study presents a significant step forward by demonstrating that end-capping a cationic helical peptide with a nucleobase substantially enhances its ability to induce liposome fusion. We show that a helical trichogin analog, Oct-K2569Tric-Lol, containing four lysine residues, induces reversible aggregation of negatively charged liposomes in a concentration-dependent manner. Remarkably, we found that the addition of a single thymine nucleobase at the C-terminus of this peptide (Oct-K2569Tric-T) transforms its activity from reversible aggregation to irreversible membrane fusion. Furthermore, we observed that the presence of complementary nucleobases at both peptide termini promotes membrane fusion even at peptide-to-lipid ratios that do not cause membrane leakage. Our findings provide a new strategy for designing more potent fusion peptides, opening possibilities for improved applications in drug delivery, cell biology research, and nanotechnology.

Indexed as

LiposomesPeptidesAmino Acid SequenceMembrane FusionLiposomesPeptidesaggregationcationic peptidehelical peptideliposomesnucleobase derivatization

Identifiers

PMID42015912
PMCPMC13356288

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.